Galapagos « Terug naar discussie overzicht

Morphosys-Galapagos, Therapeutic Antibodies

451 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 ... 19 20 21 22 23 » | Laatste
[verwijderd]
0
quote:

grapesharvester schreef op 2 maart 2014 13:16:

[...]

Daar sluit ik mij bij aan. Hoewel ik Morphosys volg omdat ik daar ook aandelen van heb, had ik de zin over de samenwerking met Galapagos gemist. Positief dat daar voortgang in zit. Hopelijk valt dit nog niet te snel op, zodat ik maandag nog kan profiteren van de koersdaling van Galapagos.
Uit de jaarrekening 2013 van de Morphosys website:
Currently, MorphoSys is pursuing various programs which are in
the early discovery phase. Included in these programs is the codevelopment
program with Galapagos NV, as well as two programs
which are in part being carried out in cooperation with external
research institutions.
[verwijderd]
0
Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody Discovery

Share with Twitter Share with LinkedIn

Share with Repost.us
WELWYN GARDEN CITY, England and BOSTON, Massachusetts, October 10, 2013 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013. The milestone is based on the generation of a stabilised (StaR®) form of the first GPCR target selected by MorphoSys, a key step that will enable its use as an antigen against which novel antibodies can be produced. Heptares will receive an undisclosed payment from MorphoSys as a result of this research milestone being achieved.
Heptares' StaR platform offers a breakthrough solution to the main challenge associated with making antibodies against GPCRs: producing purified, properly folded and functional protein when removed from the cell membrane for use as an antigen. Furthermore, StaR proteins preserve biologically relevant epitopes, thereby enabling generation of diverse panels of functional antibodies.
Under the terms of the agreement, Heptares is generating stabilised receptors for a set of GPCR disease targets proposed by MorphoSys. MorphoSys will then apply its Ylanthia® antibody library to discover and develop antibody therapeutics against these StaR proteins. MorphoSys has the right to sublicense to third parties access to these targets in conjunction with therapeutic antibody candidates. Heptares has received upfront and research funding payments, and is eligible to receive a share of future sublicensing revenues generated by MorphoSys. As part of the agreement, Heptares will also develop and commercialise one therapeutic antibody created by MorphoSys against a GPCR target selected by Heptares. In this case, MorphoSys is eligible to receive licence fees, milestones and royalties on any Ylanthia antibody developed by Heptares.
In addition to its antibody discovery collaboration with MorphoSys, Heptares is applying its StaR platform to antibody drug discovery in partnerships with MedImmune and with an undisclosed major US pharmaceutical company.
To date, Heptares has achieved all scientific milestones in its drug discovery collaborations on or ahead of schedule.
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit www.heptares.com
The HEPTARES name, the logo and STAR are trade marks of Heptares Therapeutics Ltd
Ylanthia® is a registered trademark of MorphoSys AG
SOURCE Heptares Therapeutics
[verwijderd]
0
MorphoSys's MOR208 Program to Receive Orphan Drug Designation from FDA and EMA for the Treatment of CLL/SLL
May 20, 2014 / 7:30 am, CET

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the Food & Drug Association (FDA) has granted orphan drug designation to MOR208, MorphoSys' humanized Fc engineered monoclonal antibody against CD19, for the treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL). Additionally, the Company has received a positive opinion from the European Medicines Agency (EMA) for an orphan medicinal product application for MOR208 in these indications.

en ja, na enige stilte en een wat dalend koersverloop gaat het weer omhoog met Morphosys. Dat vinden de aandeelhouders (waaronder ik en kennelijk nogal wat Amerikanen) wel leuk. Hopelijk wordt dit ook iets waar patiënten duidelijk wat aan hebben. Het is uitermate frustrerend als er helemaal niets te doen valt aan een dodelijke ziekte die mensen te vroeg uit het leven rukt.

Vertraagd 20-mei-14 10:53
Koers 63,150
Verschil +3,45 (+5,78%)
Hoog 63,200
Laag 60,920
Volume 2.414
Volume gemiddeld 921
Volume gisteren 605
Vertraagd 20-mei-14 10:53
Bied 63,094 (500)
Laat 63,308 (500)
Open 60,920
Close 59,698
52 weeks hoog 71,900
52 weeks laag 34,607
[verwijderd]
0
quote:

grapesharvester schreef op 20 mei 2014 11:08:

MorphoSys's MOR208 Program to Receive Orphan Drug Designation from FDA and EMA for the Treatment of CLL/SLL
May 20, 2014 / 7:30 am, CET

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the Food & Drug Association (FDA) has granted orphan drug designation to MOR208, MorphoSys' humanized Fc engineered monoclonal antibody against CD19, for the treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL). Additionally, the Company has received a positive opinion from the European Medicines Agency (EMA) for an orphan medicinal product application for MOR208 in these indications.

en ja, na enige stilte en een wat dalend koersverloop gaat het weer omhoog met Morphosys. Dat vinden de aandeelhouders (waaronder ik en kennelijk nogal wat Amerikanen) wel leuk. Hopelijk wordt dit ook iets waar patiënten duidelijk wat aan hebben. Het is uitermate frustrerend als er helemaal niets te doen valt aan een dodelijke ziekte die mensen te vroeg uit het leven rukt.

Vertraagd 20-mei-14 10:53
Koers 63,150
Verschil +3,45 (+5,78%)
Hoog 63,200
Laag 60,920
Volume 2.414
Volume gemiddeld 921
Volume gisteren 605
Vertraagd 20-mei-14 10:53
Bied 63,094 (500)
Laat 63,308 (500)
Open 60,920
Close 59,698
52 weeks hoog 71,900
52 weeks laag 34,607
In dunne markt nu verder gestegen vandaag + 9.3 %
Vertraagd 20-mei-14 14:15
Koers 65,270
Verschil +5,57 (+9,33%)
Hoog 65,300
Laag 60,920
Volume 3.324
Volume gemiddeld 921
Volume gisteren 605
[verwijderd]
0
Hoe snel kan je een fonds met weinig volume de afgrond in douwen

TRANSACTIES
Tijd Volume Prijs
16:26:14 63 15,125
16:26:14 18 15,125
16:25:00 32 15,125
16:23:52 16 15,160
16:23:52 142 15,160
16:23:40 71 15,170
16:23:24 29 15,170
15:49:51 50 15,200
15:42:20 43 15,220
15:34:55 165 15,210
15:34:55 210 15,210
15:34:54 169 15,405

Mag nu ook wel eens andersom svp
[verwijderd]
0
quote:

grapesharvester schreef op 20 mei 2014 14:34:

[...]

In dunne markt nu verder gestegen vandaag + 9.3 %
Vertraagd 20-mei-14 14:15
Koers 65,270
Verschil +5,57 (+9,33%)
Hoog 65,300
Laag 60,920
Volume 3.324
Volume gemiddeld 921
Volume gisteren 605
MorphoSys AG (MOR) +1.54% € 67.47

weer een stukje dichter bij all time high
[verwijderd]
0
WHITEFISH, MT / June 26, 2014 / Probably the most explosive field in biotechnology right now is that of immuno-oncology. The field is predicated on the concept that the body’s immune system can be augmented or taught to modulate cancer without the use of toxic chemotherapy agents and radiation, the standard of care today worldwide. A few years ago, the immuno-oncology research was relatively non-existent, but now it’s one of the hottest around with some big pharmas making it a primary directive. Last year, Merck & Co. (NYSE:MRK) brought back Roger Perlmutter, a man with an extensive background in immunology, for a second tour with the company, this time as EVP and President of Merck Research Laboratories, to shepherd a new path for Merck focused on oncology at the research level with an emphasis on immuno-oncology. Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (CELG), GlaxoSmithKline (NYSE:GSK), Novartis (NYSE:NVS) and more to develop antibodies to support the human immune system against cancer.

Immuno-Oncology Partnering Frenzy Is On

Just a brief look at the recent slew of activity shows that most of the biggest drugmakers in the world are heading down the immunology pathway to develop novel drugs as the next frontier of cancer research. In addition to working with MorphoSys, GlaxoSmithKine just cut a deal in which it will spend $350 million to partner with U.K-based Adaptimmune to study immuno-oncology candidates. Glaxo’s view of the future of cancer – and possibly other indications – is evident given the fact that in April they agreed to sell most of their cancer business to Novartis for up to $16 billion, while spending $7.1 billion to acquire the majority of Novartis’ vaccine business.
[verwijderd]
0
quote:

grapesharvester schreef op 30 juni 2014 23:04:

Last week, Merck enlisted MorphoSys AG in a partnership to develop therapeutic antibodies against immune checkpoints. The antibody experts at MorphoSys are in high demand, inking development agreements with Celgene (CELG), GlaxoSmithKline (NYSE:GSK), Novartis (NYSE:NVS) and more to develop antibodies to support the human immune system against cancer.

Immuno-Oncology Partnering Frenzy Is On

Just a brief look at the recent slew of activity shows that most of the biggest drugmakers in the world are heading down the immunology pathway to develop novel drugs as the next frontier of cancer research. In addition to working with MorphoSys, GlaxoSmithKine just cut a deal in which it will spend $350 million to partner with U.K-based Adaptimmune to study immuno-oncology candidates.
antibodies in demand
Morphosys in demand

Gaat dit ook wat betekenen voor Galapagos??
[verwijderd]
1
quote:

grapesharvester schreef op 30 juni 2014 23:07:

[...]

antibodies in demand
Morphosys in demand

Gaat dit ook wat betekenen voor Galapagos??
Het recent door het duo Morphosys en Galapagos gestarte fase 1 onderzoek in Mor 106 sluit aan met de trend dat antibodies in demand zijn.
Inmiddels is Morphosys na dat nieuws weer wat verder gestegen en boven haar all time high.
Je zou verwachten dat dit ook bij Galapagos een positief effect heeft, maar dat zien wij nog niet in de koers.
Uiteindelijk zal dat ook wel komen. Wat in het vat zit verzuurt niet.

Zo te zien heeft het gespeculeer over de DMC instelling bij 634 tijdelijk weer de koers wat gedrukt. Dat waait nu ook wel weer over na de verschaffing van duidelijkheid door investor relations van Galapagos.
[verwijderd]
0
MorphoSys Provides Update on the Company's Proprietary Drug Portfolio
July 28, 2014 / 7:01 am, CET

· MOR208: first clinical data from phase 2 trial planned to be presented in 2014
· MOR103: results of phase 1b trial in multiple sclerosis to be presented at ACTRIMS-ECTRIMS 2014 meeting
· MOR202: development plan expanded, introducing pomalidomide (Pomalyst®) as new combination partner
· MOR106: formal pre-clinical development commenced
· Early-stage portfolio now fully Ylanthia-based, includes programs with Merck Serono as well as first anti-GPCR programs
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) today provided an update on its proprietary portfolio including the clinical programs MOR208, MOR103 and MOR202. As these programs progress through clinical development, the company continually aims to strengthen its proprietary portfolio through new program starts, co-development and in-licensing agreements and potentially through M&A transactions.

"Our proprietary portfolio is progressing well and we believe that each program has a substantial therapeutic potential. Together with our partner Celgene we have decided that the next steps in our development plan for MOR202 will incorporate combinations with pomalidomide," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "With regards to MOR208, we intend to present first results from the ongoing NHL trial before year-end."

MOR106 - Joint antibody program with Galapagos in preclinical development

MorphoSys collaborates with Galapagos with the aim to discover and develop antibody therapies based on novel modes of action in bone and joint disease, including rheumatoid arthritis, osteoporosis and osteoarthritis. The first joint development program has recently advanced into preclinical development stage. The program named MOR106 is an antibody made using MorphoSys's next-generation antibody library Ylanthia and will be developed in inflammatory diseases.
[verwijderd]
0
En Morphosys heeft een berg cash om te investeren: 30 juni: EUR 374 miljoen, door verkoop service divisie en doordat Celgene een 10% belang nam tegen 15% boven de beurskoers zoals die zou zijn op het moment van het krijgen van teostemming. Inmiddels is beurskoers doorgestegen naar 72.50.

For the first half of 2014, MorphoSys realized a net profit from continuing operations of EUR 0.6 million compared to EUR 13.0 million in the same period of the previous year. The resulting diluted earnings per share from continuing operations for the six months ending 30 June 2014 amounted to EUR 0.02 (H1 2013: EUR 0.56). Group net profit amounted to EUR 0.6 million (H1 2013: EUR 19.0 million). The resulting diluted Group earnings per share amounted to EUR 0.02 (H1 2013: EUR 0.81).

On 30 June 2014, the Company held liquid funds and marketable securities, as well as other financial assets (reported in the balance sheet under cash and cash equivalents, available for sale financial assets, bonds, available for sale and other receivables), in the amount of EUR 374.2 million, compared to EUR 390.7 million on 31 December 2013. The net cash outflow from operations in H1 2014 was EUR 12.5 million (H1 2013: net cash inflow of EUR 0.2 million). The number of shares issued at 30 June 2014 was 26,372,584, compared to 26,220,882 on 31 December 2013.
[verwijderd]
0
quote:

flosz schreef op 16 oktober 2014 19:45:

MorphoSys Acquires Lanthipeptide Technology from Lanthio Pharma

www.morphosys.com/pressrelease/morpho...
is dit nog een klein zonnestraaltje op de donkere dagen van GLPG?
[verwijderd]
0
quote:

DirkFrank schreef op 16 oktober 2014 19:57:

[...]
is dit nog een klein zonnestraaltje op de donkere dagen van GLPG?
Morphosys is een goede partner van Galapagos, maar Gala heeft geen belang in Morpho en andersom ook niet.
Ook Morpho is weggezakt net als Ablynx en MDX health en een serie US bedrijven.

Dit nieuwsbericht heeft voor Galapagos geen gevolgen. Wel geeft het aan dat de biotech in beweging blijft en een interessante bedrijfstak is. Opmerkelijk is dat Incyte sterk herstelde vandaag, zonder verder nieuws. Het laatste nieuws van 6 oktober ging over hun JAK1 Jakafi, wat zij deels door een ander laten exploiteren en waar zij een milestone voor ontvingen van USD 60M. In september was ook Incyte fors gezakt.

Misschien kan je daar uit opmaken dat er wel iets gaat gebeuren met de Gala koers als er zo een bedrag of een veelvoud ervan wordt overgemaakt door ABBVIE of Servier.
Die kans is zeker niet uit te sluiten en wil je dat meemaken dan moet je je Gala's nog wel nog even vasthouden.
flosz
1
MorphoSys Announces Clinical Milestone in Ophthalmology Program
www.morphosys.com/pressrelease/morpho...

Ad hoc: MorphoSys Updates its 2014 Financial Guidance

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX OTC: MPSYY) today announced that it is adjusting its EBIT guidance for the current year. MorphoSys now expects a negative EBIT in the range of EUR -5 million to EUR -8 million (from previously EUR -11 million to EUR -16 million). Reasons for the change are the now confirmed receipt of a milestone payment from Janssen, which directly affects the profit line, as well as a partial shift of proprietary development expenses to 2015. Revenues are now expected at the upper end of the previously communicated guidance range of EUR 58 million to EUR 63 million.
www.morphosys.com/pressrelease/morpho...

MorphoSys to Receive Milestone Payment for Guselkumab Phase 3 Program

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that its collaborator Janssen Biotech, Inc. has initiated a phase 3 clinical trial in moderate to severe plaque-type psoriasis with the HuCAL antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.
"Our therapeutic antibody pipeline represents the main value driver for MorphoSys and we are delighted to see our third HuCAL antibody advancing into late-stage clinical development. With every phase 3 start, the time when the first HuCAL antibody drug could enter the market gets closer" commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
MorphoSys's clinical pipeline currently comprises 21 antibodies. Of these, 18 are programs that were initiated by partners, of which three are in phase 3 development, eight are in phase 2 and seven are in phase 1. From the company's proprietary portfolio, MOR202, which is being co-developed with Celgene, is in a phase 1/2a trial for multiple myeloma. MOR208 is currently being evaluated in phase 2 trials in B-ALL, NHL and CLL. The third proprietary compound, MOR103, partnered with GSK, has concluded a phase 1b/2a trial in rheumatoid arthritis and a phase 1b trial in multiple sclerosis.
www.morphosys.com/pressrelease/morpho...
[verwijderd]
0
Ook Morphosys is inderdaad goed bezig.
Qua koers nog steeds boven de EUR 70 (was enkele jaren geleden nog EUR 17), meerdere kansrijke projecten en en flinke hoeveelheid cash.

flosz
0
MorphoSys's MOR208 Program Receives Positive Opinion for Orphan Medicinal Product Designation from EMA for DLBCL

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the Company has received a positive opinion from the European Medicines Agency (EMA) on the application for orphan medicinal product designation for MOR208, MorphoSys' humanized Fc engineered monoclonal antibody against CD19, for the treatment of diffuse large B-cell lymphoma (DLBCL). The positive opinion is to be adopted by the European Commission. Earlier in December the Company had also received the orphan drug designation by the Food & Drug Administration for MOR208 in the same indication.
"2014 was an excellent year for the MOR208 program with a number of advancements. We have gained the orphan drug and orphan medicinal product status for MOR208 for the treatment of DLBCL in addition to the same status in chronic lymphocytic leukemia we announced earlier in the year. We have also received fast track designation in DLBCL and published very promising phase 2 data in DLBCL and other subtypes of NHL at this year's ASH conference. Achieving all of these important regulatory and clinical milestones in 2014 has substantially strengthened this promising cancer program," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG.
Orphan drug and orphan medicinal product status are granted by the US and European health authorities respectively to promote the development of promising therapeutics for the treatment of rare diseases affecting fewer than 200,000 people in the US annually and no more than five in 10,000 people in the European Union. Orphan drug designation includes benefits such as a seven-year period of marketing exclusivity in the United States and ten years of market exclusivity in the European Union after approval. Other potential advantages come in the form of protocol assistance, the ability to apply for research funding, tax credits for certain research expenses, and fee waivers for the regulatory procedures.
DLBCL is the most common lymphoma and accounts for approximately 25 percent of all NHLs in the developed world. The disease occurs primarily in older individuals, though it can also occur in children and young adults in rare cases.
MOR208 is an Fc-enhanced, humanized monoclonal antibody targeting the antigen CD19, which is being developed for the treatment of B-cell malignancies. The program is currently in phase 2 clinical development in chronic lymphocytic leukemia (CLL), acute lymphoblastic B-cell leukemia (B-ALL) and non-Hodgkin's lymphoma (NHL).
hugin.info/130295/R/1880000/662956.pdf
[verwijderd]
0
heel interessant flosz maar ik heb aandelen Gala. Wat kan ik nu met al deze wetenschap?
[verwijderd]
0
quote:

Dongen schreef op 15 december 2014 15:55:

heel interessant flosz maar ik heb aandelen Gala. Wat kan ik nu met al deze wetenschap?
lees even het antwoord op mijn opmerking van grapesharvester op 16 oktober.
451 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 ... 19 20 21 22 23 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 4 mrt 2024 17:35
Koers 32,070
Verschil -0,230 (-0,71%)
Hoog 32,290
Laag 31,800
Volume 118.155
Volume gemiddeld 84.886
Volume gisteren 121.102